DZ Bank’s Pacific Biosciences PACB Stock Holding History

DZ Bank’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-184,000	Closed	-$6.13M	–	980
2021 Q1	$6.13M	Buy	+184,000	New	+$6.44M	0.01%	415

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DZ Bank's PACB Position: Q2 2021 in Review

DZ Bank sold out of Pacific Biosciences (PACB) in Q2 2021, closing a stake of 184,000 shares — an estimated $6.13M sold.

DZ Bank first reported a position in PACB in Q1 2021 and held it in 1 quarter. The position peaked at $6.13M in Q1 2021. 262 funds tracked by Wall St. Rank hold PACB as of Q2 2021.

DZ Bank reported no remaining Pacific Biosciences position as of Q2 2021 after selling out during the quarter.
DZ Bank sold 184,000 Pacific Biosciences shares in Q2 2021, an estimated $6.13M.
DZ Bank first reported a position in Pacific Biosciences in Q1 2021 and held it in 1 quarter.
DZ Bank's Pacific Biosciences position peaked at $6.13M in Q1 2021.
262 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2021.

Based on DZ Bank's 13F filing for Q2 2021, filed 16 Aug 2021.